Chagas disease
A R L Teixeira, N Nitz, M C Guimaro, C Gomes and C A Santos-Buch

Postgrad. Med. J. 2006;82;788-798
doi:10.1136/pgmj.2006.047357

Updated information and services can be found at:
http://pmj.bmj.com/cgi/content/full/82/974/788

These include:

References
This article cites 92 articles, 11 of which can be accessed free at:
http://pmj.bmj.com/cgi/content/full/82/974/788#BIBL

4 online articles that cite this article can be accessed at:
http://pmj.bmj.com/cgi/content/full/82/974/788#otherarticles

Rapid responses
You can respond to this article at:
http://pmj.bmj.com/cgi/eletter-submit/82/974/788

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to Postgraduate Medical Journal go to:
http://journals.bmj.com/subscriptions/
Chagas disease

A R L Teixeira, N Nitz, M C Guimarão, C Gomes, C A Santos-Buch

Chagas disease is the clinical condition triggered by infection with the protozoan *Trypanosoma cruzi*. The infection is transmitted by triatomine insects while blood feeding on a human host. Field studies predict that one third of an estimated 18 million *T. cruzi*-infected humans in Latin America will die of Chagas disease. Acute infections are usually asymptomatic, but the ensuing chronic *T. cruzi* infections have been associated with high ratios of morbidity and mortality: Chagas heart disease leads to unexpected death in 37.5% of patients, 58% develop heart failure and die and megacolon or megaoesophagus has been associated with death in 4.5%. The pathogenesis of Chagas disease appears to be related to a parasite-induced mutation of the vertebrate genome. Currently, treatment is unsatisfactory.

American trypanosomiasis is an enzootic infection caused by the kinetoplastid flagellate *Trypanosoma cruzi*. The spread of the enzootics coincides with the distribution of the triatomine vectors from parallel 42°N in the southern US to 42°S in Patagonia, Argentina. Fossil remnants have suggested that humans arrived on the American continent about 50 000 years ago. It may be supposed that the triatomines involved in the life-cycle of *T. cruzi*, eventually transmitted the infection to Amerindians approximately 9000 years ago, probably when triatomines adapted to human dwellings in Chile and Peru, adjacent to the Atacama desert. Paleoparasitological studies showed that 97 (40.6%) of 238 mummies yielded molecular data consistent with *T. cruzi* infection. It is reasonable to suppose that American trypanosomiasis was a serious burden to Amerindians in pre-Columbian days. It is now known that *T. cruzi* infection was readily transmitted to European and African settlers living close to triatomine wild-life ecotopes in the American continents.

Chagas disease is the clinical condition associated with *T. cruzi* infection, described in the pioneering work of Dr Carlos Chagas, a Brazilian physician who worked at the Oswaldo Cruz Institute, Rio de Janeiro. He described the dividing epimastigote and the metacyclic trypomastigote forms of *T. cruzi* in the fore-gut and the hind-gut, respectively, of a *Panstrongylus megistus* captured in a human hut in the hinterland of Minas Gerais State, Brazil, in 1909. Next, he reported that he had found trypanomastigotes in the blood of a mammal, a domestic cat. Serendipitously, he investigated a 1-year-old child with fever of unknown origin and showed *T. cruzi* trypomastigotes in a peripheral blood smear by direct microscopic examination.

**T CRUZI COLONISATION OF THE HUMAN BODY**

**Insect vectors of *T. cruzi* infection**

At least 40 triatomine species can harbour *T. cruzi*, thus they are all potential transmitters of infection. The *Triatoma* sp, which adapted to the rural peri-domicile areas and domiciles of dry ecosystems of Central and South America, are the main transmitters of the infection (fig 1A, B). These species have been implicated in 10–12 million cases of Chagas disease in humans. Next in epidemiological importance are the *Rhodnius* sp, dwelling in humid tropical climates, and the ubiquitous *Panstrongylus* sp. After having a blood meal, the triatomine becomes engorged and the infective metacyclic trypomastigotes are passed in the faeces. The parasitic form enters the body when the individual scratches the skin wound inflicted by the insect’s mouth-part, or it may enter the body through permissive mucosa or conjunctival membranes. On entry into the body, the trypanomastigotes (fig 2) that invade tissue histiocytes survive the acidic parasitophorous vacuoles and leave the hostile environment to freely enter the host-cell cytoplasm. The port of entry of the infection in the skin or in the eye conjunctiva is clinically seen as an indurate, chronic inflammatory process typical of a delayed-type hypersensitivity reaction. The flagellates round up into amastigotes that undergo many cycles of multiplication by binary fission. The cell fills with amastigotes (fig 3), which will differentiate into mobile trypomastigotes (fig 4) that burst out reaching the blood stream ready to infect other cells of the body. Early papers have shown a direct relationship between host cell membrane receptor density and parasite load in tissues. In fact, every cell in the human body with the exception of neurones could be affected by *T. cruzi* colonisation in vivo. *T. cruzi* infection persists in the human body for life.

**Blood transfusion**

*T. cruzi* infection can be readily transmitted by blood transfusion. The migration of people infected by *T. cruzi* poses a threat to those countries where this insect-transmitted disease does not occur. Chagas disease has become a potential problem associated with migration from endemic areas to the US, Canada, Eastern Europe, Australia and Japan. About 8 (3%) of 250 patients from Central America were found to...

Abbreviations: kDNA, kinetoplast DNA
be seropositive in Brooklyn and Queens in New York City (CA Santos-Buch, unpublished observation), and a similar proportion was found among Nicaraguan immigrants in Washington, DC.12 Appropriate selection of blood donors, the use of sensitive screening tests and the application of a mandatory quality assurance system have maintained the safety of blood banks in most Latin American countries.13 The addition of cresyl violet to donor blood while in storage in Buenos Aires blood banks was effective in preventing the transmission of \textit{T cruzi}. The prevention of transfusion-associated protozoan infections depends mainly on selection of donors.14 Additionally, the use of more sensitive and accurate advanced molecular diagnostic tests has greatly reduced the risk of acquisition of blood-borne Chagas disease.15

Congenital transmission of \textit{T cruzi} has been reported in Latin American countries where Chagas disease is prevalent in those of reproductive age. Congenital transmission ranges from 2.5%16 in northeastern Brazil to 9.5% in Bolivia.17 Additionally, \textit{T cruzi} can be transmitted by organ transplant, by laboratory accidents and by accidental self-inoculation by hospital personnel.

**Diagnosis**

Direct demonstration of the parasite in a living mammalian host can be achieved only in the acute phase, by microscopic observation of a fresh blood smear having the motile parasites amid red cells. Chronic infections require diagnostic procedures that rely on parasite amplification before they can be detected by microscopy. Xenodiagnosis consists of allowing a parasite-free triatomine to have a blood meal from the clinically suspected candidate and examining the bug’s excrements 30 and 60 days later for the presence of the parasite.18 A parallel diagnostic attempt can be made by inoculating citrate-treated blood in axenic culture medium followed by a microscopic search for the parasite at set times. The sensitivity of both methods varies with the ability of a low number of parasites to multiply in fresh medium and requires long periods of time. The immediate detection of chronic Chagas disease relies on the indirect demonstration of specific anti-\textit{T cruzi} antibodies in patient serum or on nucleic acid-based tests.19 High-fidelity tests20 to detect specific antibodies include indirect haemagglutination, indirect immunofluorescence and the enzyme-linked immunosorbent assay. The sensitivity of individual tests ranges from 96.5% to 100% and their specificity from 87% to 98.9%. However, cross-reactive antibodies to \textit{T cruzi}-specific antigens can be present in the serum of some patients with other

**Transmission**

- **Protozoan \textit{Trypanosoma cruzi} is the causal agent.**
- **The disease is transmitted by blood-feeding triatomine bugs.**
- **Blood transfusion is the second most important mode of transmission.**
- **Placental transmission of Chagas disease can occur from the mother to child. Transmission by organ transplant and by accident is not unusual.**
kinetoplastid infections, with some intracellular parasite or bacterial diseases (eg, malaria, toxoplasmosis, paracoccidioidomycosis, tuberculosis, leprosy, syphilis and pemphigus) and with some autoimmune conditions (eg, rheumatoid arthritis, systemic lupus erythematosus, etc), albeit at much low titres. Differential diagnosis can be achieved by immunoblot assays. Diagnoses can be confirmed by the use of nucleic acid tests such as polymerase chain reaction amplification with specific primer sets followed by hybridisation with internal probes. In view of the major caveats leading to false-negatives and false-positives, it has been agreed that at least two immunological tests are required to confirm a diagnosis of Chagas disease.

Epidemiology and control

The unquestionable benefits of major insecticide-based control programmes showing abrupt drops of *T cruzi* infection in young populations need to be emphasised. It is expected that reported success will be reflected in low death rates three decades after dislodgment of domestic *Triatoma infestans*. The progress achieved thus far provides a window of opportunity before the triatomine develops resistance to the widespread and indiscriminate use of pyrethroid insecticides. More measures for control aimed at a sustainable reduction in prevalence of Chagas disease in the tropical rainforest ecosystems of Central and South America have been envisaged. Above all, control cannot be satisfactorily achieved by means other than social development and improvement of human living conditions. Particularly, interventions to prevent infection by *T cruzi* and improve children’s health mean poor housing has to be improved.

However, given the large pool of primary hosts for this enzootic disease, complete control of *T cruzi* arthropod vector transmission to the human population seems daunting. Demographic change in Latin America has been marked over the past four decades. For example, in the 1960s, 75% of the population lived in rural areas, whereas at present 81% live in metropolitan areas. As a consequence of the rural exodus, millions of people with Chagas disease live in the largest cities. The rural exodus appears to be related to the migration of people with Chagas disease to the cities for jobs and education, and thus the disease has spread to more socioeconomic classes. The spread of Chagas disease in urban areas needs to be reviewed separately on the basis of active vector-transmitted *T cruzi* infection in populations inhabiting the outskirts of major cities in many Latin American countries. Furthermore, localised transmission of acute Chagas disease has been associated with the oral route of contamination. Overall, Chagas disease in urban areas has been associated directly with about 1 death in 10 among people aged between 25 and 64 years.

Effective prophylaxis against *T cruzi* appears to be a formidable task as there are elusive biological challenges. An effective immunoprophylaxis against intracellular infection is unattainable because specific, concomitant, steady-state immunity poses a somewhat effective barrier against parasite circulation in the blood, but does not eliminate parasites that colonise non-phagocytic muscle cells, allowing the protozoa to persist throughout its host’s life. Thus, vaccination against Chagas disease is not feasible with the currently available biotechnologies. On the other hand, chemotherapy for *T cruzi* infection may be ideal because it would curtail parasitism in reservoir hosts, diminishing peridomestic insect vector dissemination. Anti-trypanosomal nitroderivatives that suppress blood parasitism show severe toxicity, requiring careful prescription.

*T cruzi* infections occur in a circumscribed region of the world that represents a relatively small market. Accordingly, pharmaceutical companies have been reluctant to invest resources for the development of vaccines and drugs to control and treat Chagas disease.

**CLINICAL MANIFESTATIONS**

**Acute Chagas disease**

Acute cases of Chagas disease are characterised by the presence of the parasite in the patient’s blood, thus allowing the demonstration of *T cruzi* trypomastigotes by direct microscopic examination of a fresh blood smear. Often, the acute phase of the infection is not perceived by the patient; 95% of the cases are asymptomatic. In the remaining symptomatic cases, the clinical manifestations of acute Chagas disease are fever, malaise, muscle and joint pains, somnolence, cramps and diarrhoea, oedema, respiratory disturbances, cyanosis and coma. Considering that <5%
Chagas disease

Epidemiology and prophylaxis

- Chagas is the most lethal endemic infectious disease in the western hemisphere.
- Pyrethroid insecticides eliminate triatomines in peridomiciles and domiciles.
- Bed nets and shields prevent the bug’s invasion of human domiciles.
- Improvement of housing conditions.
- Social and economic development.
- Education, information and communication.
- Excluding candidate blood donors through epidemiological history.
- Effective chemotherapy would diminish transmission in households.

Clinical course

- Acute infections usually subside spontaneously.
- Chronic infections are asymptomatic in two thirds of the human population.
- Chronic Chagas disease affects mostly the heart and the digestive tract.
- Arrhythmias and congestive heart failure are ominous signs of the disease.
- Megaoesophagus and megacolon cause dysphagia and constipation, respectively.

Therefore, these coinfections should be investigated in endemic and non-endemic regions of the world.

PATHOGENESIS

Two theories have been set forth to explain the pathogenesis of the lesions in Chagas disease. The parasite persistence theory postulates that Chagas lesions could be a direct consequence of the mechanical rupture of the parasitised host cell and subsequent inflammation. The autoimmune theory ascribes Chagas lesions to the rejection of parasite-free target cells by immune lymphocytes. Here we present data showing that these theories are not mutually exclusive.

Parasite persistence

Most observers agree that parasite persistence in the human host may lead to the rupture of colonised cells in the acute phase of the infection. The microscopic finding of parasite-free target cell lysys by immune effector lymphocytes has cast doubt on whether mechanical rupture is the main feature of the pathogenesis of acute disease. The difficulty in establishing a direct relationship between the intracellular presence of parasitic T cruzi forms and concomitant tissue destruction can be clearly shown in endemic areas of Chagas disease.

Autoimmunity

Experimental data have shown that autoimmunity is an important component of the pathogenesis of Chagas disease. The observed rejection of target heart fibres by the
immune system mononuclear effector cells (fig 5) appears to favour autoimmunity. The accelerated rejection of embryonic rabbit cells by immune lymphocytes derived from chronically *T cruzi*-infected rabbits has been considered evidence of autoimmunity in Chagas disease.

HISTOPATHOLOGICAL STUDY

Acute Chagas disease

*T cruzi* can parasitise any nucleated cell in the human body. Therefore, connective tissue, striated and smooth muscles, germinal cells, and phagocytic mononuclear cells can be intensely parasitised. Also, epithelial cells of the liver, kidneys, thyroid, pancreas and skin are permissive to *T cruzi*. Schwann cells of the peripheral nerve fibres, ganglia and glial

**Figure 5** Myocarditis in a kinetoplast DNA-mutated chicken. A typical feature of the Chagas lesion is the immune system mononuclear cell adherence and lyses of parasite-free target heart myofibres. Haematoxylin and eosin (H&E) stain, ×200.
cells (usually astrocytes) of the brain are parasitised, but neurones are spared. Often, amastigote parasitic forms that colonise muscle cells become inaccessible to the immune system effector cells and, therefore, can hibernate in those niches for an unknown period of time. Grossly, the heart in humans with acute disease increases in size and becomes dilated, flabby and congested. The lymph nodes near the emergence of the aorta and the pulmonary artery become engorged. In the epicardial surface, the coronary and the lymphatic vessels are dilated. These gross findings predict the presence of intense inflammatory infiltrates in the heart. Microscopically, muscle fibres and occasionally histiocytes show pseudocysts (cysts without a wall) formed by intracellular *T cruzi* amastigotes. However, a conspicuous finding in the acute phase of the infection is that of inflammatory mononuclear cell infiltrates and parasite-free host cell lyses (fig 8). These inflammatory cells, mainly macrophages and activated lymphocytes, invade muscle structures and the parasympathetic and sympathetic ganglia in the body. The lysis of parasite-free neurones is associated with adherence of the immune system mononuclear cells to the target cell outer plasma membrane. Electron microscopic studies of tissue lesions have shown inflammatory infiltrates in association with glial cell elements. Heart cell destruction by immune lymphocytes and depopulation of the neurones are hallmarks of the pathology of acute-phase Chagas disease. Although the pathology of the acute phase shows the presence of scattered parasites in the heart and nervous system, its main components are the inflammatory infiltrates and target-cell lyses. Sometimes the immune system mononuclear cells palisade the perforating meningeal blood vessels in Virchow-Robin spaces. In the brain, *T cruzi* amastigotes are more frequently found in astrocytes. These lesions are characteristic of meningoencephalitis.

**Indeterminate phase**

During the indeterminate phase of chronic *T cruzi* infections, patients do not show clinic manifestations related to heart or digestive tract lesions.60 People who were in the indeterminate phase of the infection and died of fatal accidents had no heart lesions or megaoesophagus or megacolon. Nonetheless, the indeterminate phase of the infection was established by the direct demonstration of the parasite or by phenotype and genotype markers of the cryptic infection. Microscopically, biopsies of 20 patients with these cryptic infections showed discrete, very low intensity inflammatory heart lesions.61

**Chronic Chagas disease**

The size of the heart of a patient with congestive heart failure is markedly increased and often reaches twice the normal size (fig 9). A typical gross finding of chronic Chagas heart disease is apex effacement of the left ventricle or aneurysm formation. Whenever either of these occurs, a thrombus appears in different stages of organisation. The other site of thrombus formation is the huge right atrium of the Chagas heart. Thrombi at these locations can travel to the brain and the lungs, and are frequent causes of death.

The main microscopic findings always present in a patient with chronic Chagas heart disease are inflammatory infiltrates and target heart cell lyses (fig 10). These inflammatory infiltrates are formed by macrophages, and small and large lymphocytes that migrate from the dilated lymphatic vessels to the epicardial surfaces. These immune system mononuclear cells invade the heart and produce lyses of parasite-free target heart cells. The finding of *T cruzi* amastigote nests in heart cells can be detected microscopically in 10–20% of chronic cases. Importantly, in these cases, the parasite’s intracellular nests are more often found in areas of the

**Pathogenesis**

- Parasite persistence cannot be excluded.
- Autoimmunity appears to explain parasite-free target cell destruction.
- Mechanism triggering autoimmunity needs further clarification.
- The horizontal transfer of *T cruzi* kDNA has been detected.
- Parasite-refractory chickens show kDNA mutations and evident pathology.
- Chagasic condition is present in F1 and F2 kDNA-mutated chicken.
- New genes coding chimera proteins may trigger autoimmunity.
- Investigation of the cause of autoimmunity will be a daunting task.
myocardium free of inflammatory infiltrates. Consistently, nucleic acid tests show the remnants of parasite DNA in the affected tissues of all chronically infected patients. Therefore, the hallmark of the microscopic pathology in Chagas heart disease is the destruction of the target heart cells by immune effector lymphocytes. This microscopic feature defines a minimal rejection unit (fig 11). The confluence of numerous rejection units signifies chronic Chagas myocarditis. The destroyed heart fibres are gradually replaced by fibrous scars as the inflammation subsides.

Inflammatory cells infiltrate the heart conducting system in the same manner as the contractile myocardium. The intensity of the auto-destructive process varies from one site to another in the heart; whereas some lesions are fresh, others evolve into fibrous scars as the inflammatory process fades away. With ageing, fibrous scars accumulate in the myocardium and can be found in every heart chamber, particularly in the left ventricle during late stage insufficiency.

Histochemical analysis of the sympathetic and parasympathetic nerve endings of patients with chronic Chagas disease has shown a low quantity of catecholamines and deficient acetylcholinesterase activity. Both findings are consistent with progressive autonomic denervation. Furthermore, the autonomous intracardiac nervous system in every Chagas...
heart shows typical lesions with varying degrees of intensity. The inflammatory infiltrates are evident in the parasympathetic ganglia and in the sympathetic nerve endings in the myocardium. Ganglion cells and peri-ganglion areas are associated with mononuclear cell infiltrates and proliferation of glial cells. Inflammatory cells palisade the neurones, which show degeneration and lysis. Neuronal lysis with degeneration and depopulation of neurones are the typical findings of Chagas heart disease.

Megaoesophagus and megacolon consist of gross dilation of the hollow viscera and thickening of their walls. Such lesions are associated with loss of coordination of the motility of these digestive tube segments. These changes stem from inflammatory infiltrates of the internal and external layers of smooth muscle cells of the digestive tract wall. However, inflammatory lesions particularly affect the parasympathetic neurones within the walls (fig 12). Neuronal cell depopulation occurs randomly in all segments of the digestive tract, but this is clinically more often evident in the oesophagus and the colon. Usually, a mega syndrome manifests when neurone loss reaches 55% of the units in the intramural parasympathetic ganglia. In some patients, neuronal depopulation can average 76.5% as compared with control neurone counts. The use of nucleic acid tests has shown the persistence of remnants of T cruzi DNA in tissue samples taken from mega lesions. Although the parasite persists in tissues showing mega syndromes, the literature does not document colonisation of neurones by T cruzi. As neurotoxin release by the parasite has not been shown, it is presumed that neuronolysis and depopulation are not associated with parasitism of these target cells. In contrast, neuronolysis has been associated with adherence of immune system mononuclear cells, as described for a minimal rejection unit. These observations suggest the rejection unit is the common denominator of Chagas disease pathology.

**TREATMENT**

Nifurtimox (4-(5-nitro-furylidenoamine)-tetrahydro-4-4-1,4-thiazine-1-1-dioxode) and α-benzimidazole (N-benzyl-2-nitroimidazolacetamide) are anti-trypanosome drugs used to treat the T cruzi infections. The cytotoxic and genotoxic effects associated with the drugs are related to their chemical structures, resulting in the release of electrophilic radicals on enzymatic nitro-reduction. The free radicals have been identified as the nitro-anion, H, ½ O2 and hydrogen peroxide. Drug toxicity affects the parasite and also any other innocent bystander cells in the human body. The nitro-group reduction alters the number of electrons at the external orbital, thus augmenting the mutagenic potential because free radicals bind to DNA double strands, forming adducts.

The use of nitroderivatives in the treatment of acute Chagas disease has had limited success. Physicians have used these drugs sparingly because they do not eradicate T cruzi infections in 83.5% of acute cases. Further, an indirect indication of parasite persistence is provided by positive after-treatment immunological tests. These observations explain why caution is required before using these drugs, in addition to reports showing that the use of anti-trypanosome nitroderivatives does not halt progression of the disease in patients treated for Chagas disease. For example, electrocardiographic changes in patients treated for Chagas disease did not differ statistically from those recorded in a placebo-treated cohort of patients with acute Chagas disease. Furthermore, chagasic changes on electrocardiogram have been recorded in patients 24 years after treatment with a nitroderivative compound. Moreover, in patients acutely
infected with *T. cruzi*, heart biopsies showed myocarditis, even though the patients had been treated with a nitroderivative drug. These findings strongly suggest that nitroderivative drug treatment does not prevent the onset of severe heart lesions.

In the chronic indeterminate phase, the only acceptable criterion for cure resulting from specific drug therapy for *T. cruzi* infections is the lack of detectable specific antibodies and the results of nucleic acid tests to determine evidence of the parasite’s phenotype and genotype. Results of these studies showed that 94.7% of nitroderivative drug-treated patients with chronic Chagas disease tested positive for specific antibodies to *T. cruzi* antigens. In one series that had reported 76% success in the treatment of patients with chronic Chagas disease with a nitroderivative compound, a mere 8% drop was observed in the prevalence of positive nucleic acid tests 6–18 years after chemotherapy. Importantly, it was shown that mortality was similar in treated and untreated groups of patients with chronic Chagas disease 10 years after chemotherapy.

**CONCLUSIONS**

Drug treatment for *T. cruzi* infections is considered unsatisfactory because it does not halt the progressive lesions of the heart and digestive tract of patients with chronic Chagas disease. It appears that effective treatment of Chagas disease would require a drug that does not produce undesirable effects and eradicates the infection or improves the prognosis of a sick patient. Specific chemotherapy with the drugs that are now available may not be cost effective. Nevertheless, treatment with a nitroderivative compound is clearly indicated in acutely infected patients, during the course of immune suppression and during organ transplantation of a patient with Chagas disease.

The controversy over the efficacy of treatment underlines the importance of sustained therapeutic research to control Chagas disease. The results of studies reported here suggest that the pathogenesis of the disease is related to kDNA mutations of the vertebrate host’s genome. There is a vast field of research on immunological tests and negative nucleic acid assays providing a source of kDNA that may result in cumulative mutations over time requires newly developed, targeted drugs. This is an area of scientific research that has the potential to generate health benefits for millions of people already infected with *T. cruzi*, one third of whom will develop clinical manifestations of Chagas disease.

**SELF ASSESSMENT QUESTIONS (TRUE (T) FALSE (F); ANSWERS AT THE END OF THE REFERENCES)**

1. Acute Chagas disease
   
   (A) Is usually seen in children below 15 years of age
   
   (B) Is only seen in children below 15 years of age
   
   (C) Is recognised by the finding of *T. cruzi* in blood smears
   
   (D) May be asymptomatic and subsides spontaneously
   
   (E) In <5% of the cases is associated with heart failure or meningoencephalitis

2. Chronic Chagas disease
   
   (A) Is usually seen 2–3 decades after the onset of *T. cruzi* infection
   
   (B) Is eradicated by anti-trypanosome drugs
   
   (C) Is cured by treatment as indicated by seroconversion of immunological tests and negative nucleic acid assays
   
   (D) Effects of treatment are beneficial because they prevent progressive Chagas heart disease
   
   (E) Produces megaesophagus and megacolon in the early stages of the infection only

3. Pathogenesis
   
   (A) Is related to the parasite’s pseudocyst which is easily seen in histopathological sections
   
   (B) Leads to small lesions without clinic repercussion
   
   (C) Does not cause significant rates of morbidity
   
   (D) Is usually fatal within 2 years after the onset of symptoms of heart failure
   
   (E) Can occur in the absence of *T. cruzi* infections and of specific phenotype and genotype markers of the parasite

4. Pathological study of chronic Chagas disease
   
   (A) Is partly obtained by spraying pyrethroids in the domicile and peridomicle
   
   (B) Requires control of mosquitos
   
   (C) Is controlled by vaccination in endemic areas
   
   (D) Is not affected by economic development
   
   (E) Cannot be attained by improving housing conditions

**ACKNOWLEDGEMENTS**

We thank Meire Maria de Lima for critical reading of the manuscript. NN is in receipt of a Post-Doctoral Fellowship from the Ministry of Education-CAPES, Brazil. MCG and CG are holders of scholarships from the Brazilian National Council-CNPq.

**Authors’ affiliations**

A R L Teixeira, Multidisciplinary Research Laboratory, Faculty of Medicine, University of Brasilia, Federal District, Brazil

N Nitz, M C Guimaro, C Gomes, Chagas Disease Multidisciplinary Research Laboratory, University of Brasilia, Federal District, Brazil

C A Santos-Buch*, Cornell University Medical College, New York, New York, USA

*Retired.
Funding: This work has been partially supported by Financiadora de Estudos e Projetos—FINEP, Brazil, and by NIH grant R03-A067334-01.

Competing interests: None declared.

Funding: This work has been partially supported by Financiadora de Estudos e Projetos—FINEP, Brazil, and by NIH grant R03-A067334-01.

REFERENCES


83 ANSWERS

1. (A) T, (B) F, (C) T, (D) T, (E) T
2. (A) T, (B) F, (C) F, (D) F, (E) T
3. (A) F, (B) F, (C) T, (D) F, (E) F
4. (A) F, (B) F, (C) F, (D) T, (E) F
5. (A) T, (B) F, (C) F, (D) F, (E) F